67 related articles for article (PubMed ID: 24231704)
1. [Local injection of BRM-activated killer cells into an abdominal wall tumor].
Ebina T
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1507-9. PubMed ID: 24231704
[TBL] [Abstract][Full Text] [Related]
2. [Hepatic intra-arterial infusion of biological response modifier (BRM)-activated killer immune lymphocytes to treat liver cancer].
Ebina T
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1812-4. PubMed ID: 23267895
[TBL] [Abstract][Full Text] [Related]
3. [Hepatic intra-arterial infusion of BAK immune cells to treat metastatic liver cancer].
Ebina T
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2511-3. PubMed ID: 22202430
[TBL] [Abstract][Full Text] [Related]
4. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
[TBL] [Abstract][Full Text] [Related]
5. Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels.
Ebina T; Ogama N; Shimanuki H; Kubota T; Isono N
Cancer Immunol Immunother; 2003 Sep; 52(9):555-60. PubMed ID: 14627127
[TBL] [Abstract][Full Text] [Related]
6. Effector mechanism and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells.
Ebina T; Ogama N; Shimanuki H; Kubota T; Isono N
Microbiol Immunol; 2001; 45(5):403-11. PubMed ID: 11471830
[TBL] [Abstract][Full Text] [Related]
7. [Non-small cell lung cancer--immunocell BAK (BRM activated killer) therapy].
Ebina T
Nihon Rinsho; 2006 Jul; 64(7):1339-44. PubMed ID: 16838654
[TBL] [Abstract][Full Text] [Related]
8. [Cellular immunotherapy for local recurrence of rectal cancer after surgery by activated lymphocyte administration--a case report].
Sasatomi T; Toh U; Miyagi Y; Ishibashi N; Araki Y; Ogata Y; Yamana H; Shirouzu K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1692-5. PubMed ID: 11708011
[TBL] [Abstract][Full Text] [Related]
9. [Regional adoptive immunotherapy using activated lymphocytes].
Ebina T; Isono N; Murata K; Yokoyama J; Mikuni J; Ohuchi K
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1549-52. PubMed ID: 8854802
[TBL] [Abstract][Full Text] [Related]
10. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
[TBL] [Abstract][Full Text] [Related]
12. In vitro generation of bacillus Calmette-Guérin-activated killer cells.
Brandau S; Böhle A; Thanhäuser A; Ernst M; Mattern T; Ulmer AJ; Flad HD
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S94-S100. PubMed ID: 11010832
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with activated peripheral blood lymphocytes.
Horvath J; Sinkovics JG
Leukemia; 1994 Apr; 8 Suppl 1():S121-6. PubMed ID: 8152278
[TBL] [Abstract][Full Text] [Related]
14. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
15. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
16. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
17. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
20. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
